Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma

S. Kelderman; B. Heemskerk; H. van Tinteren; R.R.H. van den Brom; G.A.P. Hospers; A.J.M. van den Eertwegh; E.W. Kapiteijn; J.W.B. de Groot; P. Soetekouw; R.L. Jansen; E. Fiets; A.J.S. Furness; A. Renn; M. Krzystanek; Z. Szallasi; P. Lorigan; M.E. Gore; T.N.M. Schumacher; J.B.A.G. Haanen; J.M.G. Larkin; C.U. Blank

doi:https://doi.org/10.1007/s00262-014-1528-9

Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma

S. Kelderman, B. Heemskerk, H. van Tinteren, R.R.H. van den Brom, G.A.P. Hospers, A.J.M. van den Eertwegh, E.W. Kapiteijn, J.W.B. de Groot, P. Soetekouw, R.L. Jansen, E. Fiets, A.J.S. Furness, A. Renn, M. Krzystanek, Z. Szallasi, P. Lorigan, M.E. Gore, T.N.M. Schumacher, J.B.A.G. Haanen, J.M.G. LarkinC.U. Blank

Medical oncology (VUmc)

Research output: Contribution to journal › Article › Academic › peer-review

264 Citations (Scopus)

Original language	Undefined/Unknown
Pages (from-to)	449-458
Journal	Cancer immunology and immunotherapy
Volume	63
Issue number	5
DOIs	https://doi.org/10.1007/s00262-014-1528-9
Publication status	Published - 2014

Access to Document

https://doi.org/10.1007/s00262-014-1528-9

Cite this

Kelderman, S., Heemskerk, B., van Tinteren, H., van den Brom, R. R. H., Hospers, G. A. P., van den Eertwegh, A. J. M., Kapiteijn, E. W., de Groot, J. W. B., Soetekouw, P., Jansen, R. L., Fiets, E., Furness, A. J. S., Renn, A., Krzystanek, M., Szallasi, Z., Lorigan, P., Gore, M. E., Schumacher, T. N. M., Haanen, J. B. A. G., ... Blank, C. U. (2014). Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma. Cancer immunology and immunotherapy, 63(5), 449-458. https://doi.org/10.1007/s00262-014-1528-9

@article{d837d7c04aed4ebe8dfaf879b3b568a9,

title = "Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma",

author = "S. Kelderman and B. Heemskerk and {van Tinteren}, H. and {van den Brom}, R.R.H. and G.A.P. Hospers and {van den Eertwegh}, A.J.M. and E.W. Kapiteijn and {de Groot}, J.W.B. and P. Soetekouw and R.L. Jansen and E. Fiets and A.J.S. Furness and A. Renn and M. Krzystanek and Z. Szallasi and P. Lorigan and M.E. Gore and T.N.M. Schumacher and J.B.A.G. Haanen and J.M.G. Larkin and C.U. Blank",

year = "2014",

doi = "https://doi.org/10.1007/s00262-014-1528-9",

language = "Undefined/Unknown",

volume = "63",

pages = "449--458",

journal = "Cancer immunology and immunotherapy",

issn = "0340-7004",

publisher = "Springer Science and Business Media Deutschland GmbH",

number = "5",

}

Kelderman, S, Heemskerk, B, van Tinteren, H, van den Brom, RRH, Hospers, GAP, van den Eertwegh, AJM, Kapiteijn, EW, de Groot, JWB, Soetekouw, P, Jansen, RL, Fiets, E, Furness, AJS, Renn, A, Krzystanek, M, Szallasi, Z, Lorigan, P, Gore, ME, Schumacher, TNM, Haanen, JBAG, Larkin, JMG & Blank, CU 2014, 'Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma', Cancer immunology and immunotherapy, vol. 63, no. 5, pp. 449-458. https://doi.org/10.1007/s00262-014-1528-9

TY - JOUR

T1 - Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma

AU - Kelderman, S.

AU - Heemskerk, B.

AU - van Tinteren, H.

AU - van den Brom, R.R.H.

AU - Hospers, G.A.P.

AU - van den Eertwegh, A.J.M.

AU - Kapiteijn, E.W.

AU - de Groot, J.W.B.

AU - Soetekouw, P.

AU - Jansen, R.L.

AU - Fiets, E.

AU - Furness, A.J.S.

AU - Renn, A.

AU - Krzystanek, M.

AU - Szallasi, Z.

AU - Lorigan, P.

AU - Gore, M.E.

AU - Schumacher, T.N.M.

AU - Haanen, J.B.A.G.

AU - Larkin, J.M.G.

AU - Blank, C.U.

PY - 2014

Y1 - 2014

U2 - https://doi.org/10.1007/s00262-014-1528-9

DO - https://doi.org/10.1007/s00262-014-1528-9

M3 - Article

C2 - 24609989

SN - 0340-7004

VL - 63

SP - 449

EP - 458

JO - Cancer immunology and immunotherapy

JF - Cancer immunology and immunotherapy

IS - 5

ER -